Physicians' Academy for Cardiovascular Education

SGLT2 inhibition & Heart Failure: Lessons from EMPA REG Outcome

May 9, 2017 - Paris, France - Per-Henrik Groop, MD - ESC Heart Failure 2017

Diabetes and diabetic kidney disease are associated with increased risk of cardiovascular disease and remarkably shortened life expectancy. Prof. Per-Henrik Groop explains the clinical implications of SGLT2-inhibtion, based on EMPA REG Outcome.

Video navigation menu

  • Cardiovascular consequences of diabetes and diabetic kidney disease 00:43
  • Effect of glucose lowering on diabetic late complications 02:43
  • Lessons from EMPA REG Outcome 05:30
  • Clinical implications of SGLT2 inhibition - as important as RAAS inhibition? 09:58

Educational information

This lecture was part of a CME accredited symposium: Heart failure, Diabetes, and Renal Dysfunction: Time for a more unified approach held at Heart Failure 2017 in Paris.

Educational objectives:

Disclosures

Professor Per-Henrik Groop is currently a Professor of Nephrology (Chair) at the University of Helsinki, Chief Physician at the Division of Nephrology, Helsinki University Central Hospital and Principal Investigator of the Finnish Diabetic Nephropathy (FinnDiane) Study at the Folkhälsan Research Center in Helsinki, Finland.

Funding

This EBAC accredited symposium was funded by an unrestricted educational grant received from Boehringer-Ingelheim/Lilly

View slides